Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Smith

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Nature Reviews. Rheumatology|September 23, 2017
Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.
Nature Reviews. Rheumatology|December 20, 2017
Corrigendum: Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.
Journal of the National Cancer Institute|August 12, 2025
Childhood Cancer Data Initiative: Expanded access to tumor molecular profiling for children, adolescents, and young adultsJoseph Flores-Toro, Subhashini Jagu, Malcolm Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
European Journal of Cancer (Oxford, England : 1990)|September 29, 2020
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Kimberly Stegmaier, Franck Bourdeaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Toward a drug development path that targets metastatic progression in osteosarcomaChand Khanna, Timothy M Fan, Richard Gorlick, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancerAndrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew D J Pearson, Sara Federico, Susanne A Gatz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug AdministrationAndrew D J Pearson, Elly Barry, Yael P Mossé, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Nature Reviews. Rheumatology|September 23, 2017
Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.
Nature Reviews. Rheumatology|December 20, 2017
Corrigendum: Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.
Journal of the National Cancer Institute|August 12, 2025
Childhood Cancer Data Initiative: Expanded access to tumor molecular profiling for children, adolescents, and young adultsJoseph Flores-Toro, Subhashini Jagu, Malcolm Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
European Journal of Cancer (Oxford, England : 1990)|September 29, 2020
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Kimberly Stegmaier, Franck Bourdeaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Toward a drug development path that targets metastatic progression in osteosarcomaChand Khanna, Timothy M Fan, Richard Gorlick, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancerAndrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew D J Pearson, Sara Federico, Susanne A Gatz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug AdministrationAndrew D J Pearson, Elly Barry, Yael P Mossé, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 19